Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Med Genomics ; 7: 36, 2014 Jun 18.
Article in English | MEDLINE | ID: mdl-24943349

ABSTRACT

BACKGROUND: The outcome of patients with metastatic colorectal carcinoma (mCRC) following first line therapy is poor, with median survival of less than one year. The purpose of this study was to identify candidate therapeutically targetable somatic events in mCRC patient samples by whole genome sequencing (WGS), so as to obtain targeted treatment strategies for individual patients. METHODS: Four patients were recruited, all of whom had received > 2 prior therapy regimens. Percutaneous needle biopsies of metastases were performed with whole blood collection for the extraction of constitutional DNA. One tumor was not included in this study as the quality of tumor tissue was not sufficient for further analysis. WGS was performed using Illumina paired end chemistry on HiSeq2000 sequencing systems, which yielded coverage of greater than 30X for all samples. NGS data were processed and analyzed to detect somatic genomic alterations including point mutations, indels, copy number alterations, translocations and rearrangements. RESULTS: All 3 tumor samples had KRAS mutations, while 2 tumors contained mutations in the APC gene and the PIK3CA gene. Although we did not identify a TCF7L2-VTI1A translocation, we did detect a TCF7L2 mutation in one tumor. Among the other interesting mutated genes was INPPL1, an important gene involved in PI3 kinase signaling. Functional studies demonstrated that inhibition of INPPL1 reduced growth of CRC cells, suggesting that INPPL1 may promote growth in CRC. CONCLUSIONS: Our study further supports potential molecularly defined therapeutic contexts that might provide insights into treatment strategies for refractory mCRC. New insights into the role of INPPL1 in colon tumor cell growth have also been identified. Continued development of appropriate targeted agents towards specific events may be warranted to help improve outcomes in CRC.


Subject(s)
Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/genetics , Genetic Predisposition to Disease , Genome, Human/genetics , Molecular Targeted Therapy , Mutation/genetics , Sequence Analysis, DNA , Aged , Blotting, Western , Cell Proliferation , Colorectal Neoplasms/pathology , DNA Copy Number Variations/genetics , Gene Silencing , HCT116 Cells , HEK293 Cells , Humans , INDEL Mutation/genetics , Male , Middle Aged , Neoplasm Metastasis , Phosphatidylinositol 3-Kinases/metabolism , Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases , Phosphoric Monoester Hydrolases/genetics , Polymorphism, Single Nucleotide/genetics , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins p21(ras) , RNA, Small Interfering/metabolism , Signal Transduction/genetics , ras Proteins/genetics
2.
N Engl J Med ; 366(2): 141-9, 2012 Jan 12.
Article in English | MEDLINE | ID: mdl-22236224

ABSTRACT

BACKGROUND: Family history is a significant risk factor for prostate cancer, although the molecular basis for this association is poorly understood. Linkage studies have implicated chromosome 17q21-22 as a possible location of a prostate-cancer susceptibility gene. METHODS: We screened more than 200 genes in the 17q21-22 region by sequencing germline DNA from 94 unrelated patients with prostate cancer from families selected for linkage to the candidate region. We tested family members, additional case subjects, and control subjects to characterize the frequency of the identified mutations. RESULTS: Probands from four families were discovered to have a rare but recurrent mutation (G84E) in HOXB13 (rs138213197), a homeobox transcription factor gene that is important in prostate development. All 18 men with prostate cancer and available DNA in these four families carried the mutation. The carrier rate of the G84E mutation was increased by a factor of approximately 20 in 5083 unrelated subjects of European descent who had prostate cancer, with the mutation found in 72 subjects (1.4%), as compared with 1 in 1401 control subjects (0.1%) (P=8.5x10(-7)). The mutation was significantly more common in men with early-onset, familial prostate cancer (3.1%) than in those with late-onset, nonfamilial prostate cancer (0.6%) (P=2.0x10(-6)). CONCLUSIONS: The novel HOXB13 G84E variant is associated with a significantly increased risk of hereditary prostate cancer. Although the variant accounts for a small fraction of all prostate cancers, this finding has implications for prostate-cancer risk assessment and may provide new mechanistic insights into this common cancer. (Funded by the National Institutes of Health and others.).


Subject(s)
Germ-Line Mutation , Homeodomain Proteins/genetics , Prostatic Neoplasms/genetics , Chromosomes, Human, Pair 17 , Genetic Linkage , High-Throughput Nucleotide Sequencing , Humans , Male , Middle Aged , Pedigree , Prostate/pathology , Prostatic Neoplasms/pathology , Sequence Analysis, DNA
3.
Mol Cancer Ther ; 7(9): 3071-80, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18765825

ABSTRACT

Multimeric ligands are ligands that contain multiple binding domains that simultaneously target multiple cell-surface proteins. Due to cooperative binding, multimeric ligands can have high avidity for cells (tumor) expressing all targeting proteins and only show minimal binding to cells (normal tissues) expressing none or only some of the targets. Identifying combinations of targets that concurrently express in tumor cells but not in normal cells is a challenging task. Here, we describe a novel approach for identifying such combinations using genome-wide gene expression profiling followed by immunohistochemistry. We first generated a database of mRNA gene expression profiles for 28 pancreatic cancer specimens and 103 normal tissue samples representing 28 unique tissue/cell types using DNA microarrays. The expression data for genes that encode proteins with cell-surface epitopes were then extracted from the database and analyzed using a novel multivariate rule-based computational approach to identify gene combinations that are expressed at an efficient binding level in tumors but not in normal tissues. These combinations were further ranked according to the proportion of tumor samples that expressed the sets at efficient levels. Protein expression of the genes contained in the top ranked combinations was confirmed using immunohistochemistry on a pancreatic tumor tissue and normal tissue microarrays. Coexpression of targets was further validated by their combined expression in pancreatic cancer cell lines using immunocytochemistry. These validated gene combinations thus encompass a list of cell-surface targets that can be used to develop multimeric ligands for the imaging and treatment of pancreatic cancer.


Subject(s)
Cell Membrane/metabolism , Gene Expression Profiling , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/pathology , Algorithms , Cell Line, Tumor , Gene Expression Regulation, Neoplastic , Genes, Neoplasm , Humans , Immunohistochemistry , Ligands , Oligonucleotide Array Sequence Analysis , Reproducibility of Results , Tissue Array Analysis
4.
Neurobiol Dis ; 18(3): 528-36, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15755680

ABSTRACT

Oculopharyngeal muscular dystrophy (OPMD) is a late-onset disorder caused by a (GCG)n trinucleotide repeat expansion in the poly(A) binding protein nuclear-1 (PABPN1) gene, which in turn leads to an expanded polyalanine tract in the protein. We generated transgenic mice expressing either the wild type or the expanded form of human PABPN1, and transgenic animals with the expanded form showed clear signs of abnormal limb clasping, muscle weakness, coordination deficits, and peripheral nerves alterations. Analysis of mitotic and postmitotic tissues in those transgenic animals revealed ubiquitinated PABPN1-positive intranuclear inclusions (INIs) in neuronal cells. This latter observation led us to test and confirm the presence of similar INIs in postmortem brain sections from an OPMD patient. Our results indicate that expanded PABPN1, presumably via the toxic effects of its polyalanine tract, can lead to inclusion formation and neurodegeneration in both the mouse and the human.


Subject(s)
Ataxia/genetics , Ataxia/metabolism , Muscle Weakness/genetics , Muscle Weakness/metabolism , Poly(A)-Binding Protein I/biosynthesis , Poly(A)-Binding Protein I/genetics , Trinucleotide Repeat Expansion/genetics , Animals , Humans , Mice , Mice, Inbred C57BL , Mice, Transgenic , Peptides/genetics , Peptides/physiology , Poly(A)-Binding Protein I/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...